Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eflornithine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 0.96 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ARG1 | P05089 | 3/20 | 0.61 |
| ▸ | ARG2 | P78540 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflornithine, (S)- SCHEMBL6779172 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL1322403 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL7208883 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL6779173 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL6779168 | 1.00 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL5051665 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL4510 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL1397750 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL4809264 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL3238104 | 0.98 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4352518-A2 | METHODS OF TREATING CANCER WITH CD-40 AGONISTS | Apexigen America, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| CN-117795341-A | Methods of treating cancer using CD-40 agonists | 埃派斯进美国有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-110191876-A | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | 奥巴斯治疗股份有限公司 | 2019-08-30 | — | — | CN | claimed |
| WO-2009114695-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2009-09-17 | — | — | WO | claimed |
| US-6936187-B2 | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use | CHILDREN'S HOSPITAL RESEARCH FOUNDATION | 2005-08-30 | — | — | US | claimed |
| EP-3368029-B1 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | USWM LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137642-A1 | METHODS OF TREATING PATIENTS HAVING TYPE 1 DIABETES WITH EFLORNITHINE | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-12605349-B2 | Methods of treating grade 3 astrocytoma | Orbus Therapeutics, Inc. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12582625-B2 | Methods for treating neuroblastoma | USWM, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260060950-A1 | METHODS OF TREATING GRADE 3 ASTROCYTOMA | ORBUS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4687900-A2 | COMBINATION TREATMENT FOR OVARIAN CANCER | The Johns Hopkins University (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| WO-1998014188-A1 | DFMO AND TAXOL FOR THE TREATMENT OR PREVENTION OF BREAST CANCER | ILEX ONCOLOGY, INC. (US) | 1998-04-09 | — | — | WO | disclosed |
| US-5614557-A | ADMINISTERING (DIFLUOROMETHYL)ORNITHINE OR SALT WITH METHYLGLYOXAL BIS(GUANYLHYDRAZONE) | MARION MERRELL ET COMPAGNIE C/O MERRELL PHARMACEUTICALS INC. (US) | 1997-03-25 | — | — | US | disclosed |
| US-4560795-A | α-Halomethyl derivatives of α-amino acids | Merrell Dow France et Cie. (FR) | 1985-12-24 | — | — | US | disclosed |
| US-4496588-A | HALOMETHYL DERIVATIVES OF A-AMINO ACID | MERRELL TORAUDE ET COMPAGNIE (FR) | 1985-01-29 | — | — | US | disclosed |
| US-4438270-A | DECARBOXYLASE INHIBITORS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-03-20 | — | — | US | disclosed |
| US-4413141-A | INHIBITOR OF ORNITHINE DECARBOXYLASE | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-11-01 | — | — | US | disclosed |
| US-4330559-A | 2,5-DIAMINO-2-FLUOROMETHYLPENTANOIC ACIDS OR DERIVATIVES | MERRELL-TORAUDE ET CIE (FR) | 1982-05-18 | — | — | US | disclosed |
| US-4309442-A | 2,5-DIAMINO-2-FLUOROMETHYLPENTANOIC ACID OR DERIVATIVE THEREOF | MERRELL TORAUDE ET COMPAGNIE (FR) | 1982-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137642-A1 | METHODS OF TREATING PATIENTS HAVING TYPE 1 DIABETES WITH EFLORNITHINE | IAPP, GLP1R, IRS1 | ODC1 702/4885BLM 4850/4885LMNA 1467/4885 |
| US-12605349-B2 | Methods of treating grade 3 astrocytoma | IDH3A, IDH3B, TP53 | ODC1 2635/4885BLM 799/4885LMNA 2046/4885 |
| US-12582625-B2 | Methods for treating neuroblastoma | ODC1, DDC, CD2 | ODC1 1/4885BLM 4671/4885LMNA 1444/4885 |
| US-20260060950-A1 | METHODS OF TREATING GRADE 3 ASTROCYTOMA | IDH3A, IDH3B, TP53 | ODC1 2322/4885BLM 2398/4885LMNA 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.